

Sean M Murphy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1966267/publications.pdf>

Version: 2024-02-01

63
papers

1,606
citations

361413

20
h-index

330143

37
g-index

65
all docs

65
docs citations

65
times ranked

1888
citing authors

#	ARTICLE	IF	CITATIONS
1	The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1-10.	1.9	274
2	Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders. <i>New England Journal of Medicine</i> , 2016, 374, 1232-1242.	27.0	255
3	Urban Blight Remediation as a Cost-Beneficial Solution to Firearm Violence. <i>American Journal of Public Health</i> , 2016, 106, 2158-2164.	2.7	99
4	Economic Evaluations of Opioid Use Disorder Interventions. <i>Pharmacoeconomics</i> , 2016, 34, 863-887.	3.3	79
5	Cost-Effectiveness of Buprenorphine+Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse. <i>Annals of Internal Medicine</i> , 2019, 170, 90.	3.9	50
6	Cost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2016, 161, 119-126.	3.2	45
7	Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH). <i>Implementation Science</i> , 2019, 14, 48.	6.9	42
8	Projected Estimates of Opioid Mortality After Community-Level Interventions. <i>JAMA Network Open</i> , 2021, 4, e2037259.	5.9	37
9	Assessing Differences in the Availability of Opioid Addiction Therapy Options: Rural Versus Urban and American Indian Reservation Versus Nonreservation. <i>Journal of Rural Health</i> , 2017, 33, 102-109.	2.9	35
10	An economic evaluation of a contingency-management intervention for stimulant use among community mental health patients with serious mental illness. <i>Drug and Alcohol Dependence</i> , 2015, 153, 293-299.	3.2	34
11	Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. <i>Addiction</i> , 2017, 112, 1440-1450.	3.3	34
12	The cost of opioid use disorder and the value of aversion. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108382.	3.2	30
13	PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 9.	2.6	27
14	Mental Health Costs of Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 40-48.	1.9	26
15	Will converting naloxone to over-the-counter status increase pharmacy sales?. <i>Health Services Research</i> , 2019, 54, 764-772.	2.0	25
16	Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108764.	3.2	25
17	Determinants of Adolescent Suicidal Ideation: Rural Versus Urban. <i>Journal of Rural Health</i> , 2014, 30, 175-185.	2.9	24
18	Non-medical prescription opioid use and violent behaviour among adolescents. <i>Journal of Child and Adolescent Mental Health</i> , 2014, 26, 35-47.	1.7	24

#	ARTICLE	IF	CITATIONS
19	Physician Time Burden Associated with Querying Prescription Drug Monitoring Programs. <i>Pain Medicine</i> , 2018, 19, 1952-1960.	1.9	23
20	Determinants of buprenorphine treatment for opioid dependence. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 315-319.	2.8	22
21	Medical marijuana laws are associated with increases in substance use treatment admissions by pregnant women. <i>Addiction</i> , 2019, 114, 1593-1601.	3.3	21
22	Healthcare utilization patterns among persons who use drugs during the COVID-19 pandemic. <i>Journal of Substance Abuse Treatment</i> , 2021, 121, 108177.	2.8	21
23	Implementation of methadone therapy for opioid use disorder in Russia – a modeled cost-effectiveness analysis. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2017, 12, 4.	2.2	20
24	Medication treatment for opioid use disorder in expectant mothers (MOMs): Design considerations for a pragmatic randomized trial comparing extended-release and daily buprenorphine formulations. <i>Contemporary Clinical Trials</i> , 2020, 93, 106014.	1.8	20
25	Massachusetts Justice Community Opioid Innovation Network (MassJOIN). <i>Journal of Substance Abuse Treatment</i> , 2021, 128, 108275.	2.8	20
26	Estimated impact of supervised injection facilities on overdose fatalities and healthcare costs in New York City. <i>Journal of Substance Abuse Treatment</i> , 2019, 106, 79-88.	2.8	17
27	Economic modeling of reSET-O, a prescription digital therapeutic for patients with opioid use disorder. <i>Journal of Medical Economics</i> , 2021, 24, 61-68.	2.1	17
28	Economic Evaluations of Pharmacologic Treatment for Opioid Use Disorder: A Systematic Literature Review. <i>Value in Health</i> , 2021, 24, 1068-1083.	0.3	17
29	Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting. <i>JAMA Network Open</i> , 2020, 3, e2029676.	5.9	17
30	Opioid Misuse Among Adolescents: New Evidence from a Misclassification Analysis. <i>Applied Health Economics and Health Policy</i> , 2015, 13, 181-192.	2.1	14
31	Cost-effectiveness of Hepatitis C Virus Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. <i>Clinical Infectious Diseases</i> , 2020, 70, 1397-1405.	5.8	13
32	Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island. <i>International Journal of Drug Policy</i> , 2021, 98, 103435.	3.3	13
33	The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation. <i>Contemporary Clinical Trials</i> , 2021, 104, 106359.	1.8	12
34	Association of co-occurring opioid or other substance use disorders with increased healthcare utilization in patients with depression. <i>Translational Psychiatry</i> , 2021, 11, 265.	4.8	12
35	Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108221.	3.2	11
36	A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study. <i>Contemporary Clinical Trials</i> , 2021, 110, 106379.	1.8	11

#	ARTICLE	IF	CITATIONS
37	Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings. <i>American Journal of Drug and Alcohol Abuse</i> , 2015, 41, 88-92.	2.1	10
38	A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail. <i>Journal of Substance Abuse Treatment</i> , 2021, 128, 108241.	2.8	10
39	The opioid use disorder core outcomes set (OUDâ€‘COS) for treatment research: findings from a Delphi consensus study. <i>Addiction</i> , 2022, 117, 2438-2447.	3.3	10
40	Cost of pharmacotherapy for opioid use disorders following inpatient detoxification. <i>American Journal of Managed Care</i> , 2018, 24, 526-531.	1.1	9
41	Health economic design for cost, cost-effectiveness and simulation analyses in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108336.	3.2	8
42	Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial. <i>Contemporary Clinical Trials</i> , 2020, 91, 105993.	1.8	8
43	Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials. <i>Addiction Science & Clinical Practice</i> , 2020, 15, 15.	2.6	8
44	Communityâ€‘based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island. <i>Addiction</i> , 2022, 117, 1372-1381.	3.3	8
45	Economic evaluation in the National Drug Abuse Treatment Clinical Trials Network: Past, present, and future. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 18-27.	2.8	7
46	The â€œRealâ€‘Number of Washington State Adolescents Using Marijuana, and Why: A Misclassification Analysis. <i>Substance Use and Misuse</i> , 2019, 54, 89-96.	1.4	6
47	Core outcomes set for research on the treatment of opioid use disorder (COS-OUD): the National Institute on Drug Abuse Clinical Trials Network protocol for an e-Delphi consensus study. <i>Trials</i> , 2021, 22, 102.	1.6	6
48	An Economic Evaluation of Coordinated Specialty Care (CSC) Services for First-Episode Psychosis in the U.S. Public Sector. <i>Journal of Mental Health Policy and Economics</i> , 2018, 21, 123-130.	0.6	6
49	Criminal justice measures for economic data harmonization in substance use disorder research. <i>Health and Justice</i> , 2018, 6, 17.	2.1	5
50	Using a randomized controlled trial to test whether modifications to contingency management improve outcomes for heavy drinkers with serious mental illness. <i>Contemporary Clinical Trials</i> , 2018, 69, 92-98.	1.8	5
51	Predictors of tobacco and alcohol co-use from ages 15 to 32: The Amsterdam Growth and Health Longitudinal Study.. <i>Experimental and Clinical Psychopharmacology</i> , 2018, 26, 549-559.	1.8	5
52	Assessing informed consent in an opioid relapse prevention study with adults under current or recent criminal justice supervision. <i>Journal of Substance Abuse Treatment</i> , 2017, 81, 66-72.	2.8	4
53	Implementation of a Nationwide Health Economic Consultation Service to Assist Substance use Researchers: Lessons Learned. <i>Substance Abuse</i> , 2018, 39, 185-189.	2.3	4
54	Health economic analyses of the justice community opioid innovation network (JOIN). <i>Journal of Substance Abuse Treatment</i> , 2021, 128, 108262.	2.8	4

#	ARTICLE	IF	CITATIONS
55	Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release. <i>Journal of Substance Abuse Treatment</i> , 2022, , 108835.	2.8	4
56	Patient Activation, Depressive Symptoms, and Self-Rated Health: Care Management Intervention Effects among High-Need, Medically Complex Adults. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 5690.	2.6	3
57	Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis. <i>Addiction</i> , 2022, 117, 2450-2461.	3.3	3
58	Personal Control Over Decisions to Participate in Research by Persons With Histories of Both Substance Use Disorders and Criminal Justice Supervision. <i>Journal of Empirical Research on Human Research Ethics</i> , 2018, 13, 160-172.	1.3	2
59	Harmonizing healthcare and other resource measures for evaluating economic costs in substance use disorder research. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 32.	2.2	1
60	Opioid Use Associated With Higher Costs Among Patients With Inflammatory Bowel Disease. <i>Crohn's & Colitis</i> 360, 2021, 3, .	1.1	1
61	Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysis. <i>Addiction</i> , 2021, 116, 3444-3453.	3.3	1
62	Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109265.	3.2	1
63	Design and protocol of the Buprenorphine plus Outpatient Parenteral Antimicrobial Therapy (B-OPAT) study: a randomized clinical trial of integrated outpatient treatment of opioid use disorder and severe, injection-related infections. <i>Therapeutic Advances in Infectious Disease</i> , 2022, 9, 204993612211080.	1.8	0